George Simeone

Curevo, Inc. is a clinical stage company based in South Korea that aims to bring next generation vaccines to the market quickly and efficiently. The company is based in Seattle, WA. The company's partners include Mogam Institute for Biomedical Research and GC Pharma. Curevo is currently in phase 2 of a shingles study to evaluate the safety, tolerability, and immunogenicity of their vaccine. The company's goal is to reduce the burden of infectious disease with a focus on safe and highly effective shingles and varicella vaccines. Curevo was founded in 2018, and the CEO is George Simeone.

Curevo, Inc. is a clinical stage company based in South Korea that aims to bring next generation vaccines to the market quickly and efficiently. The company is based in Seattle, WA. The company's partners include Mogam Institute for Biomedical Research and GC Pharma. Curevo is currently in phase 2 of a shingles study to evaluate the safety, tolerability, and immunogenicity of their vaccine. The company's goal is to reduce the burden of infectious disease with a focus on safe and highly effective shingles and varicella vaccines. Curevo was founded in 2018, and the CEO is George Simeone.

Curevo, Inc. is a clinical stage company based in South Korea that aims to bring next generation vaccines to the market quickly and efficiently. The company is based in Seattle, WA. The company's partners include Mogam Institute for Biomedical Research and GC Pharma. Curevo is currently in phase 2 of a shingles study to evaluate the safety, tolerability, and immunogenicity of their vaccine. The company's goal is to reduce the burden of infectious disease with a focus on safe and highly effective shingles and varicella vaccines. Curevo was founded in 2018, and the CEO is George Simeone.

Curevo, Inc. is a clinical stage company based in South Korea that aims to bring next generation vaccines to the market quickly and efficiently. The company is based in Seattle, WA. The company's partners include Mogam Institute for Biomedical Research and GC Pharma. Curevo is currently in phase 2 of a shingles study to evaluate the safety, tolerability, and immunogenicity of their vaccine. The company's goal is to reduce the burden of infectious disease with a focus on safe and highly effective shingles and varicella vaccines. Curevo was founded in 2018, and the CEO is George Simeone.

Curevo, Inc. is a clinical stage company based in South Korea that aims to bring next generation vaccines to the market quickly and efficiently. The company is based in Seattle, WA. The company's partners include Mogam Institute for Biomedical Research and GC Pharma. Curevo is currently in phase 2 of a shingles study to evaluate the safety, tolerability, and immunogenicity of their vaccine. The company's goal is to reduce the burden of infectious disease with a focus on safe and highly effective shingles and varicella vaccines. Curevo was founded in 2018, and the CEO is George Simeone.